[A Case of Metaplastic Breast Cancer Treated with Neoadjuvant Chemotherapy Combined with Pembrolizumab].

Nakatani Y; Terakawa H; Kawata C; Kurokawa Y; Mohri R; Saito H; Hirata M; Tsuji T; Yamamoto D; Moriyama H; Kinoshita J; Kitahara T; Ikeda H; Kawashima H; Inaki N

← 뒤로

[A Case of Metaplastic Breast Cancer Treated with Neoadjuvant Chemotherapy Combined with Pembrolizumab].

Gan to kagaku ryoho. Cancer & chemotherapy 2025 Vol.52(13) p. 1120-1122

Nakatani Y, Terakawa H, Kawata C, Kurokawa Y, Mohri R, Saito H, Hirata M, Tsuji T, Yamamoto D, Moriyama H, Kinoshita J, Kitahara T, Ikeda H, Kawashima H, Inaki N

원문 ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Metaplastic breast carcinoma, a rare subtype(<1% of breast cancers), is typically triple-negative with a poor prognosis.

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Nakatani Y, Terakawa H, et al. (2025). [A Case of Metaplastic Breast Cancer Treated with Neoadjuvant Chemotherapy Combined with Pembrolizumab].. Gan to kagaku ryoho. Cancer & chemotherapy, 52(13), 1120-1122.

MLA Nakatani Y, et al.. "[A Case of Metaplastic Breast Cancer Treated with Neoadjuvant Chemotherapy Combined with Pembrolizumab].." Gan to kagaku ryoho. Cancer & chemotherapy, vol. 52, no. 13, 2025, pp. 1120-1122.

PMID 41546268

Abstract

Metaplastic breast carcinoma, a rare subtype(<1% of breast cancers), is typically triple-negative with a poor prognosis. The KEYNOTE-522 trial established pembrolizumab plus chemotherapy as a standard treatment for early-stage, high-risk triple-negative breast cancer. We report a case of metaplastic carcinoma with squamous differentiation achieving pathological complete response after neoadjuvant pembrolizumab-based chemoimmunotherapy. This case suggests that pembrolizumab-based chemoimmunotherapy may be a promising option for chemoresistant metaplastic carcinoma.

MeSH Terms

Humans; Antibodies, Monoclonal, Humanized; Neoadjuvant Therapy; Female; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Middle Aged; Metaplasia